Esteller M.



Manel Esteller graduated in Medicine at the Universidad de Barcelona in 1992, where he also obtained his Ph.D. degree specializing in molecular genetics of endometrial carcinoma, in 1996. He was an Invited Researcher at the School of Biological and Medical Sciences at the University of St. Andrews, (Scotland, UK) during which time his research interests focused on the molecular genetics of inherited breast cancer, and at the University of California San Diego (UCSD) in 2014, where he studied the chromatin conformation at the genomics level. From 1997 to 2001, Esteller was a Postdoctoral Fellow and a Research Associate at the Johns Hopkins University and School of Medicine, (Baltimore, USA) where he studied DNA methylation and human cancer. His work was decisive in establishing promoter hypermethylation of tumour suppressor genes as a common hallmark of all human tumours. From October 2001 to September 2008 Manel Esteller was the Leader of the CNIO Cancer Epigenetics Laboratory, where his principal area of research were the alterations in DNA methylation, histone modifications and chromatin in human cancer. Since October 2008, Dr Esteller is the Director of the Cancer Epigenetics and Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, Leader of the Cancer Epigenetics Group, Professor of Genetics in the School of Medicine of the University of Barcelona, and an ICREA Research Professor. His current research is devoted to the establishment of the epigenome maps of normal and transformed cells, the study of the interactions between epigenetic modifications and non-coding RNAs, and the development of new epigenetic drugs for cancer therapy. Author of more than four hundred original peer-reviewed manuscripts in biomedical sciences with a total Impact Factor of 3,383.306, he is also a Member of numerous international scientific societies, Editorial Boards and reviewer for many journals and funding agencies. Dr Esteller is also Associate Editor for Cancer Research, The Lancet Oncology, Carcinogenesis and The Journal of The National Cancer Institute, Editor-in-Chief of Epigenetics and President of the Epigenetics Society. His work has received, among other, the Best Young Cancer Researcher Award by the European School of Medical Oncology (1999), First Prize in Basic Research at the Johns Hopkins University and Medical Institution (1999), Best Young Investigator Award from the European Association for Cancer Research (2000), Carcinogenesis Award (2005), Beckman-Coulter Award (2006), Fondazione Piemontese per la Ricerca sul Cancro (FPRC) Award (2006), Swiss Bridge Award (2006), Innovation Award from the Commonwealth of Massachussets (2007), Human Frontier Science Program Award (2007), DEbiopharm-EPFL Award (2009), Dr. Josef Steiner Cancer Research Award (2009), Lilly Foundation Preclinical Biomedical Research Award (2009), World Health Summit Award (2010), National Award in Genetics (2011), the European Research Council Advanced Grant (2011) and the European Research Council Proof of Concept Grant (2014).

Record last modified Oct 10, 2018 2:07:04 PM